Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis

NCT05002764 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT05002764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05002764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2021
Completion date
July 1, 2023
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis